var data={"title":"Doxycycline: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Doxycycline: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6077?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">see &quot;Doxycycline: Drug information&quot;</a> and <a href=\"topic.htm?path=doxycycline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Doxycycline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163331\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acticlate;</li>\n      <li>Adoxa Pak 1/100 [DSC];</li>\n      <li>Adoxa Pak 1/150 [DSC];</li>\n      <li>Adoxa Pak 2/100 [DSC];</li>\n      <li>Adoxa [DSC];</li>\n      <li>Alodox Convenience [DSC];</li>\n      <li>Avidoxy;</li>\n      <li>Doryx;</li>\n      <li>Doryx MPC;</li>\n      <li>Doxy 100;</li>\n      <li>Mondoxyne NL;</li>\n      <li>Monodox [DSC];</li>\n      <li>Morgidox;</li>\n      <li>NicAzelDoxy 30 [DSC];</li>\n      <li>NicAzelDoxy 60 [DSC];</li>\n      <li>Ocudox [DSC];</li>\n      <li>Okebo;</li>\n      <li>Oracea;</li>\n      <li>TargaDOX;</li>\n      <li>Vibramycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163332\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Doxy;</li>\n      <li>Apo-Doxy Tabs;</li>\n      <li>Apprilon;</li>\n      <li>Dom-Doxycycline;</li>\n      <li>Doxycin;</li>\n      <li>Doxytab;</li>\n      <li>Periostat;</li>\n      <li>PHL-Doxycycline;</li>\n      <li>PMS-Doxycycline;</li>\n      <li>Teva-Doxycycline;</li>\n      <li>Vibramycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047096\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Tetracycline Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51198882\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anthrax:</b> Very limited data available (AAP [Bradley 2014]): Term neonates:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prophylaxis; post-exposure (inhalation or cutaneous); prior to susceptibility testing or penicillin-resistant strains: Oral: 2.2 mg/kg/dose every 12 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutaneous infection without systemic involvement: </i>\n      <b>Note:</b> Doxycycline is an option if first-line therapy (ie, ciprofloxacin) is unavailable or patient unable to tolerate; for naturally-occurring infection, usual treatment duration is 7 to 10 days; in the event of biological weapon exposure, additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2.2 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic anthrax excluding meningitis:</i> <b>Note:</b> Not recommended for meningitis or disseminated infection when meningitis cannot be ruled out. Doxycycline is an alternative to clindamycin as protein synthesis inhibitor and should be used in combination with a bactericidal antimicrobial (eg, fluoroquinolone, carbapenem, or vancomycin). Duration of therapy at least 14 days or longer until patient clinically stable. Additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: IV: Loading dose: 4.4 mg/kg once, then 2.2 mg/kg/dose every 12 hours; treat for &ge;2 to 3 weeks until condition stable</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Step-down: Oral: 2.2 mg/kg/dose every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047087\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">see &quot;Doxycycline: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing:</b> Children &ge;8 years and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours, maximum daily dose: 200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax </b>(AAP [Bradley 2014])<b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis; post-exposure (inhalation or cutaneous); prior to susceptibility testing or penicillin-resistant strains: <b>Note:</b> Doxycycline is a preferred option or ciprofloxacin: Infants, Children, and Adolescents: Treatment duration: 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &lt;45 kg: Oral: 2.2 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &ge;45 kg: Oral: 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment; susceptible strains:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cutaneous infection without systemic involvement: </i>\n      <b>Note:</b> Doxycycline is an option if first-line therapy (ie, ciprofloxacin) is unavailable or patient unable to tolerate; for naturally-occurring infection, usual treatment duration is 7 to 10 days; in the event of biological weapon exposure, additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;45 kg: Oral: 2.2 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &ge;45 kg: Oral: 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Systemic anthrax, excluding meningitis: </i>\n      <b>Note:</b> Not recommended for meningitis or disseminated infection when meningitis cannot be ruled out. Doxycycline is an alternative to clindamycin as protein synthesis inhibitor and should be used in combination with a bactericidal antimicrobial (eg, fluoroquinolone, carbapenem, or vancomycin). Duration of therapy at least 14 days or longer until patient clinically stable; additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;45 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial: IV: Loading dose: 4.4 mg/kg once, then 2.2 mg/kg/dose every 12 hours; may transition to oral therapy for patients without signs of active infection who are able to tolerate oral therapy and patient/caregiver adherent to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Step-down: Oral: 2.2 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &ge;45 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial: IV: Loading dose: 200 mg once, then 100 mg every 12 hours; may transition to oral therapy for patients without signs of active infection who are able to tolerate oral therapy and patient/caregiver adherent to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Step-down: Oral: 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brucellosis:</b> Limited data available: Children &ge;8 years and Adolescents: Oral: 1 to 2 mg/kg/dose twice daily for 6 weeks; maximum dose: 100 mg/dose; use in combination with rifampin or an aminoglycoside (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chlamydial infections, uncomplicated (sexually transmitted <i>C. trachomatis)</i>:</b> Adolescents: Oral: 100 mg twice daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease:</b> Limited data available (IDSA [Wormser 2006]): Children &ge;8 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis, postexposure: Oral: 4 mg/kg/dose once as a single dose; maximum dose: 200 mg/dose; initiate within 72 hours of tick removal</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Early Lyme</i>\n      <i> disease: </i>Oral: 2 mg/kg/dose twice daily for 10 to 21 days (usual duration: 14 days); maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Lyme arthritis (no neurologic involvement):</i> Oral: 2 mg/kg/dose twice daily for 28 days; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningitis, neurologic Lyme disease</i>: Oral: 2 to 4 mg/kg/dose twice daily for 10 to 28 days; maximum dose: 200 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria:</b> Children &ge;8 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: Oral: 2.2 mg/kg/dose once daily starting 1 to 2 days before travel to the area with endemic infection, continuing daily during travel and for 4 weeks after leaving endemic area; maximum daily dose: 100 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: Oral, IV: 2.2 mg/kg/dose twice daily for 7 days; maximum dose: 100 mg/dose (CDC 2013); for uncomplicated cases, combination therapy with quinine sulfate is recommended; in severe cases, combination therapy with quinidine gluconate should be used; <b>Note:</b> Duration of either quinine sulfate or quinidine gluconate is region-specific; consult CDC for current recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia</b>, <b>community-acquired; presumed or proven atypical infection (<i>Mycoplasma pneumoniae, Chlamydophila pneumoniae)</i>: </b>Children &ge;8 years and Adolescents: Oral: 1 to 2 mg/kg/dose twice daily for 10 days (IDSA [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Q fever <i>(</i><i>Coxiella burnetii)</i></b> (preferred therapy): Children and Adolescents: Oral: 2.2 mg/kg/dose twice daily for 14 days; maximum dose: 100 mg/dose; in children &lt;8 years with mild or uncomplicated disease, may consider treatment duration of 5 days, and if longer treatment required, may consider alternate therapy (trimethoprim/sulfamethoxazole) (CDC [Anderson 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin/soft tissue infections; MRSA or community-acquired cellulitis (purulent) </b>(IDSA [Liu 2011]): Children &ge;8 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;45 kg: Oral: 2 mg/kg/dose every 12 hours for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;45 kg: Oral: 100 mg twice daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tickborne rickettsial disease (Rocky Mountain spotted fever), ehrlichiosis, or anaplasmosis:</b> Children and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours; maximum dose: 100 mg/dose; treat for minimum of 5 to 7 days; continue for at least 3 days after defervescence and clinical improvement observed. Severe or complicated disease may require longer treatment; anaplasmosis should be treated for 10 days (CDC [Biggs 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No adjustment necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163303\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Morgidox: 50 mg, 100 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibramycin: 100 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 150 mg [DSC] [contains fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mondoxyne NL: 50 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mondoxyne NL: 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mondoxyne NL: 100 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Monodox: 75 mg [DSC], 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Okebo: 75 mg, 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oracea: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alodox Convenience: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Morgidox: 1 x 50 mg, 2 x 100 mg, 1 x 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), cetyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocudox: 50 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NicAzelDoxy 30: 100 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6 aluminum lake, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NicAzelDoxy 60: 100 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6 aluminum lake, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as hyclate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxy 100: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as monohydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/5 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibramycin: 25 mg/5 mL (60 mL) [contains brilliant blue fcf (fd&amp;c blue #1), methylparaben, propylparaben; raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/5 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as calcium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vibramycin: 50 mg/5 mL (473 mL) [contains butylparaben, propylene glycol, propylparaben, sodium metabisulfite; raspberry-apple flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acticlate: 75 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acticlate: 150 mg [scored; contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TargaDOX: 50 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 75 mg, 100 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as monohydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 50 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 75 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa: 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa Pak 1/100: 100 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa Pak 2/100: 100 mg [DSC] [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adoxa Pak 1/150: 150 mg [DSC] [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avidoxy: 100 mg [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as hyclate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doryx: 50 mg, 150 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doryx: 200 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doryx MPC: 120 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg, 150 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163288\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23449398\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">see &quot;Doxycycline: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alodox Convenience kits contain doxycycline tablets 20 mg, plus eyelid cleanser</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morgidox kits contain doxycycline capsules 100 mg, plus AcuWash moisturizing Daily Cleanser</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NizAzel Doxy kits contain doxycycline tablets 100 mg, plus NicAzel FORTE dietary supplement tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocudox kits contain doxycycline capsules 50 mg, plus eyelid cleanser and Tears Again Advanced eyelid spray</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047100\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer capsules or tablets with adequate amounts of fluid (to avoid throat irritation); avoid antacids, infant formula, milk, dairy products, and iron for 1 hour before or 2 hours after administration of doxycycline (unless extemporaneously prepared in the instance of public health emergency when milk or pudding is appropriate); may be administered with food to decrease GI upset; shake suspension well before use</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Doryx: May break up the tablet and sprinkle the delayed release pellets on a spoonful of applesauce. Do <b>not</b> crush or damage the delayed release pellets; loss or damage of pellets prevents using the dose. Swallow the Doryx/applesauce mixture immediately without chewing. Discard mixture if it cannot be used immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: For IV use only; administer over 1 to 4 hours; avoid rapid infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sclerosing agent:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">To control pleural effusions associated with metastatic tumors: Instill into the pleural space through a thoracostomy tube following drainage of the accumulated pleural fluid; clamp the tube then remove the fluid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For recurrent malignant pleural effusions: Administer via chest tube lavage, clamp tube for 24 hours then drain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163323\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, tablet, delayed-release tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Syrup, oral suspension: Store below 30&deg;C (86&deg;F); protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. Stability of IV infusion varies based on solution; refer to manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047099\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Treatment of infections caused by susceptible <i>Rickettsia</i>, <i>Chlamydia</i>, and <i>Mycoplasma</i>; alternative to mefloquine for malaria prophylaxis; treatment for syphilis, uncomplicated <i>Neisseria gonorrhoeae</i>, <i>Listeria</i>, <i>Actinomyces israelii</i>, <i>Fusobacterium fusiforme</i>, and <i>Clostridium</i> infections in penicillin-allergic patients; used for community-acquired pneumonia and other common infections due to susceptible organisms; anthrax due to <i>Bacillus anthracis</i>, including inhalational anthrax (postexposure); treatment of infections caused by uncommon susceptible gram-negative and gram-positive organisms, including <i>Borrelia recurrentis</i>, <i>Ureaplasma urealyticum</i>, <i>Haemophilus ducreyi</i>, <i>Yersinia pestis</i>, <i>Francisella tularensis</i>, <i>Vibrio cholerae</i>, <i>Campylobacter fetus</i>, <i>Brucella</i> spp, <i>Bartonella bacilliformis</i>, and <i>Calymmatobacterium granulomatis</i>, Q fever, Lyme disease; treatment of inflammatory lesions associated with rosacea; adjunct to amebicides for intestinal amebiasis; adjunct for treatment of severe acne (FDA approved in ages &ge;8 years and adults); treatment of inflammatory lesions (papules and pustules) associated with rosacea (Oracea&reg;: FDA approved in adults). Has also been used for community-acquired MRSA cellulitis, in ehrlichiosis and management of malignant pleural effusions with intrapleural administration. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163372\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Doxycycline may be confused with dicyclomine, doxepin, doxylamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Doxy100 may be confused with Doxil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Monodox may be confused with Maalox</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oracea may be confused with Orencia</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vibramycin may be confused with vancomycin, Vibativ</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oracea (US brand name) is marketed in Canada under the brand name Apprilon</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163369\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin hyperpigmentation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase, increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain, diarrhea, esophageal ulcer, esophagitis, upper abdominal pain, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Fungal infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasal congestion, nasopharyngitis, sinus headache, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> Rare but important or life-threatening: Anaphylactoid reaction, anaphylaxis, angioedema, anorexia, bulging fontanel, <i>Clostridium difficile </i>associated diarrhea, dental discoloration, DRESS syndrome, dysphagia, enamel hypoplasia, enterocolitis, eosinophilia, erythema multiforme, erythematous rash, exacerbation of systemic lupus erythematosus, exfoliative dermatitis, glossitis, headache, hemolytic anemia, hepatotoxicity, hypersensitivity reaction, increased blood urea nitrogen (dose related), increased serum ALT, inflammatory anogenital lesion, intracranial hypertension, maculopapular rash, nausea, neutropenia, pancreatitis, pericarditis, pseudomembranous colitis, serum sickness, skin hyperpigmentation, skin photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, thyroid disease (brown/black discoloration; no dysfunction reported), toxic epidermal necrolysis, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163310\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periostat, Apprilon [Canadian products]: Additional contraindications: Use in infants and children &lt;8 years of age or during second or third trimester of pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163292\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI inflammation/ulceration: Esophagitis and ulcerations (sometimes severe) may occur; patients with dysphagia and/or retrosternal pain may require assessment for esophageal lesions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Rarely occurs; if symptomatic, assess LFTs and discontinue drug.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity syndromes: Severe skin reactions (eg, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported. Discontinue therapy for serious hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; this does not occur with use of doxycycline in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension: Intracranial hypertension (pseudotumor cerebri) has been reported; headache, blurred vision, diplopia, vision loss, and/or papilledema may occur. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patient until stable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: May cause photosensitivity; discontinue at first sign of skin erythema. Use skin protection and avoid prolonged exposure to sunlight and ultraviolet light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tissue hyperpigmentation: May induce hyperpigmentation in many organs, including nails, bone, skin (diffuse pigmentation as well as over sites of scars and injury), eyes, thyroid, visceral tissue, oral cavity (adult teeth, mucosa, alveolar bone), sclerae, and heart valves independently of time or amount of drug administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: Safety and effectiveness have not been established for treatment of periodontitis in patients with coexistent oral candidiasis; use with caution in patients with a history or predisposition to oral candidiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May cause tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration (more common with long-term use, but observed with repeated, short courses) when used during tooth development (last half of pregnancy, infancy, and childhood &le;8 years of age); manufacturer states to use in children &le;8 years of age only when the potential benefits outweigh the risks in severe or life threatening conditions (eg, anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies. Limited use between 6 to 7 years of age has minimal effect on the color of permanent incisors (CDC 2006). Recommended in treatment of anthrax exposure (CDC 2001), tickborne rickettsial diseases (CDC 2006), and Q fever (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oracea, Apprilon [Canadian product]: Should not be used for the treatment or prophylaxis of bacterial infections because the lower dose of drug per capsule may be subefficacious and promote resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfite sensitivity: Syrup may contain sodium metabisulfite, which may cause allergic reactions in certain individuals (eg, asthmatic patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Acne: The American Academy of Dermatology acne guidelines recommend doxycycline as adjunctive treatment for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Concomitant topical therapy with benzoyl peroxide or a retinoid should be administered with systemic antibiotic therapy (eg, doxycycline) and continued for maintenance after the antibiotic course is completed (AAD [Zaenglein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Limitations of use: Malaria prophylaxis: Doxycycline does not completely suppress asexual blood stages of <i>Plasmodium</i> strains; does not suppress <i>P. falciparum's</i> sexual blood stage gametocytes. Patients completing a regimen may still transmit the infection to mosquitoes outside endemic areas.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856139\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tooth staining or enamel hypoplasia of developing teeth is a known concern with the use of tetracycline-class of antibiotics in children &lt;8 years of age based on experience with older tetracyclines which bind to calcium more readily than doxycycline. A cohort analysis of 58 children who were exposed to doxycycline for treatment of Rocky Mountain Spotted Fever when &lt;8 years of age reported no visible tetracycline-like tooth staining of permanent teeth and recommended dose and duration compared to a control group of 213 children not exposed to doxycycline; the cohort received a total of 107 courses of doxycycline (multiple courses), mean duration: 7.3 days (range: 1 to 10 days), and mean dose: 2.3 mg/kg/day (Todd 2015). An analysis of 31 asthmatic children who received doxycycline also reported no evidence of tooth staining. A meta-analysis of the combined data reported a 0% prevalence rate for tooth staining (CDC [Biggs 2016]; Todd 2015). Retrospective data suggests that at standard doses, children &lt;8 years could receive up to 5 courses of doxycycline without detectable evidence of tooth staining (AAP [Bradley 2014]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administration of tetracycline 25 mg/kg/day was associated with decreased fibular growth rate in premature infants (reversible with discontinuation of drug); bulging fontanels have been reported in infants.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163358\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163297\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13255&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Tetracyclines may decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Tetracyclines. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Doxycycline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 h before sucroferric oxyhydroxide.  Specific dose separation guidelines for other tetracyclines are not presently available.  No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163326\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Doxycycline serum levels may be slightly decreased if taken with high-fat meal or milk. Administration with iron or calcium may decrease doxycycline absorption. May decrease absorption of calcium, iron, magnesium, zinc, and amino acids. Management: Administer Doryx and Doryx MPC without regard to meals. Administer Oracea and doxycycline 20 mg tablet on an empty stomach 1 hour before or 2 hours after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163300\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163313\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Tetracyclines cross the placenta (Mylonas 2011). Therapeutic doses of doxycycline during pregnancy are unlikely to produce substantial teratogenic risk, but data are insufficient to say that there is no risk. In general, reports of exposure have been limited to short durations of therapy in the first trimester. Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Doxycycline is the recommended agent for the treatment of Rocky Mountain spotted fever (RMSF) in pregnant women (CDC [Biggs 2016]). For other indications, many guidelines consider use of doxycycline to be contraindicated during pregnancy, or to be a relative contraindication in pregnant women if other agents are available and appropriate for use (Anderson 2013; CDC 2011; HHS [OI adult 2015]; Stevens 2014; Workowski [CDC 2015]; IDSA [Wormser 2006]). Doxycycline should not be used for the treatment of rosacea in pregnant women. When systemic antibiotics are needed for dermatologic conditions, other agents are preferred (Kong 2013; Murase 2014). As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047095\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With long-term use, monitor BUN, hematologic, and hepatic function tests; observe for changes in bowel frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163291\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">20 mg tablets and capsules (Periostat [Canadian product]): Proposed mechanism: Has been shown to inhibit collagenase activity in vitro. Also has been noted to reduce elevated collagenase activity in the gingival crevicular fluid of patients with periodontal disease. Systemic levels do not reach inhibitory concentrations against bacteria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163309\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Almost completely absorbed from the GI tract; average peak plasma concentration may be reduced ~20% (30% for Doryx MPC) by high-fat meal or milk</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely into body tissues and fluids including synovial, pleural, prostatic, seminal fluids, and bronchial secretions; saliva, aqueous humor, and CSF penetration is poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not hepatic; partially inactivated in GI tract by chelate formation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Reduced at high pH; may be clinically significant in patients with gastrectomy, gastric bypass surgery or who are otherwise deemed achlorhydric</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 18 to 22 hours; End-stage renal disease: 18 to 25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Immediate release: 1.5 to 4 hours; delayed release: 2.8 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (30%); urine (23% to 40%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163308\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">If a public health emergency is declared and liquid doxycycline is unavailable for the treatment of anthrax, emergency doses may be prepared for children or adults who cannot swallow tablets.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Add 20 mL of water to one 100 mg tablet. Allow tablet to soak in the water for 5 minutes to soften. Crush into a fine powder and stir until well mixed. Appropriate dose should be taken from this mixture. To increase palatability, mix with food or drink. If mixing with drink, add 15 mL of  milk, chocolate milk, chocolate pudding, or apple juice to the appropriate dose of mixture. If using apple juice, also add 4 teaspoons of sugar. Doxycycline and water mixture may be stored at room temperature for up to 24 hours.</p>\n    <div class=\"reference\">US Food and Drug Administration, Center for Drug Evaluation and Research, &ldquo;Public Health Emergency Home Preparation Instructions for Doxycycline.&rdquo; Available at   <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130996.htm&amp;token=eOAl4+1qn/DPeqwrJV1jWsf9KilooALKe1axTSIQvv7QK32LiEzpYsK+R1GUECRGXYF51VF9amZXG1D83TfPQmIuqwxO+Y1ZFVWZjdlxoYBnc0GscrY3EmH1OOJmBqD/&amp;TOPIC_ID=13255\" target=\"_blank\">http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130996.htm</a></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163312\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Doxycycline Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $653.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Oracea Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $769.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Doxycycline Hyclate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (50): $112.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $307.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Doxycycline Monohydrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $155.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $1,691.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $118.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,479.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mondoxyne NL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $576.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $912.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $631.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Morgidox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $389.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $643.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Okebo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $440.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vibramycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $717.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Morgidox Combination)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 x 50 mg (1): $389.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 x 100 mg (1): $643.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 x 100 mg (1): $1,000.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Doxy 100 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $22.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Doxycycline Hyclate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $18.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Doxycycline Monohydrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (60 mL): $26.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Vibramycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (60 mL): $49.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Vibramycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (473 mL): $602.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Doryx MPC Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $450.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Doryx Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (120): $1,565.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $2,897.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Doxycycline Hyclate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (120): $1,407.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $613.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,314.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $1,759.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $2,605.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Acticlate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $2,285.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $2,285.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Doxycycline Hyclate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $118.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $1,871.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $307.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,871.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Doxycycline Monohydrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $335.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $498.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $246.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $274.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (TargaDOX Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $863.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163315\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abraxil (CL);</li>\n      <li>Agidox (LK);</li>\n      <li>Alldox (ZW);</li>\n      <li>Amermycin (HK, TH);</li>\n      <li>Apdox (BD);</li>\n      <li>Asdoxin (ET);</li>\n      <li>Azudoxat (DE);</li>\n      <li>Bactidox (PH);</li>\n      <li>Bassado (IT);</li>\n      <li>Biodoxi (IN);</li>\n      <li>Biomixin (MX);</li>\n      <li>By-Mycin (IE);</li>\n      <li>Ciclonal (MX);</li>\n      <li>Clordox (BR);</li>\n      <li>Cyclidox (ZA);</li>\n      <li>Cyclindox (VN);</li>\n      <li>Cytragen (PH);</li>\n      <li>Dagramycine (LU);</li>\n      <li>Dentacline (KR);</li>\n      <li>Dentistar (KR);</li>\n      <li>Deoxymykoin (CZ);</li>\n      <li>Doc-100 (TZ);</li>\n      <li>Docyl (TH);</li>\n      <li>Doinmycin (TW);</li>\n      <li>Dokat (TR);</li>\n      <li>Doksiciklin (HR);</li>\n      <li>Doksin (TR);</li>\n      <li>Doksybene (UA);</li>\n      <li>Domiken (MX);</li>\n      <li>Doryx (AU, NZ);</li>\n      <li>Dosil (ES);</li>\n      <li>Dotur (UY);</li>\n      <li>Doxat (BH, CY, EG, IQ, IR, JO, KW, LB, LY, MT, OM, QA, SA, SY, VN, YE);</li>\n      <li>Doxicap (ZW);</li>\n      <li>Doxiclat (ES);</li>\n      <li>Doximed (FI);</li>\n      <li>Doximycin (FI);</li>\n      <li>Doxin (PH, TH);</li>\n      <li>Doxine (NZ);</li>\n      <li>Doxipil (ES);</li>\n      <li>Doxiplus (PE);</li>\n      <li>Doxitin (LV);</li>\n      <li>Doxman (LK);</li>\n      <li>Doxsig (AU);</li>\n      <li>Doxxkam (PH);</li>\n      <li>Doxy (LB);</li>\n      <li>Doxy 200 (LU);</li>\n      <li>Doxy A (BD);</li>\n      <li>Doxy Komb (LU);</li>\n      <li>Doxy M (EE);</li>\n      <li>Doxy SMB (LU);</li>\n      <li>Doxy-1 (IN);</li>\n      <li>Doxy-100 (DE, NZ);</li>\n      <li>Doxybene (CZ);</li>\n      <li>Doxycap (HK, SG);</li>\n      <li>Doxycin (SA);</li>\n      <li>Doxyclin (ZW);</li>\n      <li>Doxycline (LU, TH);</li>\n      <li>Doxycyclin AL (HU);</li>\n      <li>Doxycycline (BE);</li>\n      <li>Doxycycline-Ethypharm (LU);</li>\n      <li>Doxycycline-Eurogenerics (LU);</li>\n      <li>Doxydar (JO, QA, SA);</li>\n      <li>Doxyhexal (CZ, HU, LU);</li>\n      <li>Doxylag (BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Doxylan (LV);</li>\n      <li>Doxylcap (TH);</li>\n      <li>Doxylets (LU);</li>\n      <li>Doxylin (AU, IL, NO, NZ);</li>\n      <li>Doxyline (SG);</li>\n      <li>Doxylis (FR);</li>\n      <li>Doxymycin (TW, ZA);</li>\n      <li>Doxymycine (LU);</li>\n      <li>Doxypharm (HU);</li>\n      <li>Dumoxin (BH, CY, EG, ID, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Duo Di (CN);</li>\n      <li>Duradox (AE, KW, QA);</li>\n      <li>Efracea (GB, IE);</li>\n      <li>Empadoxine (ET);</li>\n      <li>Etidoxina (CO);</li>\n      <li>Genobiotic-Doxi (MX);</li>\n      <li>Grandoxy (AE, QA);</li>\n      <li>Granudoxy (FR, LU);</li>\n      <li>Hiramicin (HR);</li>\n      <li>Impedox (BD);</li>\n      <li>Interdoxin (ID);</li>\n      <li>Lenteclin (ET);</li>\n      <li>Madoxy (TH);</li>\n      <li>Mardox (BD);</li>\n      <li>Medomycin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, ZM, ZW);</li>\n      <li>Medox (PH);</li>\n      <li>Microdox (LK, ZW);</li>\n      <li>Miraclin (IT);</li>\n      <li>Monocin (KR);</li>\n      <li>Monodox (CO);</li>\n      <li>Oracea (ES);</li>\n      <li>Periostat (GB);</li>\n      <li>Policycline (TH);</li>\n      <li>Radox (BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Remycin (MT, TR, TW);</li>\n      <li>Retadox (LB);</li>\n      <li>Retens (MT);</li>\n      <li>Revidox (LK);</li>\n      <li>Servidoxine (EC);</li>\n      <li>Siadocin (TH);</li>\n      <li>Sigadoxin (PT);</li>\n      <li>Supracyclin (AT, CH, PE);</li>\n      <li>Supramycina (EC, PY);</li>\n      <li>Tabocine (AE, QA);</li>\n      <li>Tarocin (KW);</li>\n      <li>Tarocine (BH);</li>\n      <li>Tedoxy (PH);</li>\n      <li>Tenutan (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Teradox (PH);</li>\n      <li>Teradoxin (ET);</li>\n      <li>Tolexine (FR, HK);</li>\n      <li>Tolexine Ge (FR);</li>\n      <li>Torymycin (TH);</li>\n      <li>Tremesal (VE);</li>\n      <li>Unidox (BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PL, QA, RO, SA, SY, YE);</li>\n      <li>Unidoxy (KR);</li>\n      <li>Veemycin (TH);</li>\n      <li>Verboril (AR);</li>\n      <li>Vibradox (DK, PT);</li>\n      <li>Vibramicina (AR, CL, CO, MX, PE, PT, UY, VE);</li>\n      <li>Vibramitsyn (UA);</li>\n      <li>Vibramycin (AE, AT, AU, BB, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, DE, EG, ET, GB, GH, GM, GN, GR, GY, HK, HU, ID, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PH, PK, QA, RU, SA, SC, SD, SE, SL, SN, SR, SY, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Vibramycin N (KR);</li>\n      <li>Vibramycine (FR);</li>\n      <li>Vibratab (BE, LU);</li>\n      <li>Vibraveineuse (FR);</li>\n      <li>Vibravenos (AT, DE);</li>\n      <li>Viclorax (PE);</li>\n      <li>Vidoxy (KR);</li>\n      <li>Vivradoxil (MX);</li>\n      <li>Weibamycin (TW);</li>\n      <li>Withamycin (TW);</li>\n      <li>Yong Xi (CN);</li>\n      <li>Zadorin (BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO. Drug use during breast-feeding. <i>Clin Pharm</i>. 1991;10(8):594-624.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/1934918/pubmed\" target=\"_blank\" id=\"1934918\">1934918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24777226/pubmed\" target=\"_blank\" id=\"24777226\">24777226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). <i>CDC Yellow Book 2018 Health Information for International Travel</i>. New York: Oxford University Press; 2018; Chapter 3. Available at <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Center for Disease Control and Prevention (CDC), &ldquo;Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis - United States,&rdquo; <i>MMWR Recomm Rep</i>, 2006 55(RR-4):1-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16572105/pubmed\" target=\"_blank\" id=\"16572105\">16572105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at <a href=\"http://www.cdc.gov/malaria/pdf/treatmenttable.pdf%20\" target=\"_blank\">http://www.cdc.gov/malaria/pdf/treatmenttable.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Update: Investigation of Anthrax Associated with Intentional Exposure and Interim Public Health Guidelines, October 2001,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2001, 50(41):889-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11686472 /pubmed\" target=\"_blank\" id=\"11686472 \">11686472 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, and Blumer JL, &quot;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&quot; <i>Paediatr Drugs</i>, 2002, 4(12):817-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/12431134/pubmed\" target=\"_blank\" id=\"12431134\">12431134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services [HHS] Panel on Opportunistic Infections [OI] in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf</a>. Updated March 1, 2016. Accessed July 30, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inglesby TV, Henderson DA, Bartlett JG, et al, &ldquo;Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense,&rdquo; <i>JAMA</i>, 1999, 281(18):1735-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/10328075/pubmed\" target=\"_blank\" id=\"10328075\">10328075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23657872/pubmed\" target=\"_blank\" id=\"23657872\">23657872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus Aureus</i> Infections in Adults and Children: Executive Summary,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):e1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mylonas I, &quot;Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration,&quot; <i>Arch Gynecol Obstet</i>, 2011, 283(1):7-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/20814687/pubmed\" target=\"_blank\" id=\"20814687\">20814687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant patients. <i>Dermatol Ther</i>. 2013;26(4):302-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23914887/pubmed\" target=\"_blank\" id=\"23914887\">23914887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2009 Report of the Committee on Infectious Diseases.</i> 28th ed. Pickering LK, ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stern EJ, Uhde KB, Shadomy SV, et al, &quot;Conference Report on Public Health and Clinical Guidelines for Anthrax,&quot; <i>Emerg Infect Dis</i>, 2008, 14(4). Available at <a href=\"http://wwwnc.cdc.gov/eid/article/14/4/07-0969.htm\" target=\"_blank\">http://wwwnc.cdc.gov/eid/article/14/4/07-0969.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/18394267/pubmed\" target=\"_blank\" id=\"18394267\">18394267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. <i>J Pediatr</i>. 2015;166(5):1246-1251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/25794784/pubmed\" target=\"_blank\" id=\"25794784\">25794784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tokuda G, Yuasa M, Mihara S et al. Clinical study of doxycycline in obstetrical and gynecological fields. <i>Chemotherapy (Tokyo)</i>. 1969;17:339-344. Available at <a href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+100\" target=\"_blank\">http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+100</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3478018/pubmed\" target=\"_blank\" id=\"3478018\">3478018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Berman S, and Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot;<i> MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/24528911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. Brucellosis in humans and animals. 2006. Available at http://www.who.int/csr/resources/publications/Brucellosis.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed May 17, 2016.26897386</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13255 Version 286.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F163331\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F163332\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047096\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F51198882\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047087\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F163303\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F163288\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23449398\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047100\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F163323\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047099\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F163372\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F163369\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F163310\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F163292\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25856139\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F163358\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F163297\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F163326\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F163300\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F163313\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047095\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F163291\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F163309\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F163308\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F163312\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F163315\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13255|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">Doxycycline: Drug information</a></li><li><a href=\"topic.htm?path=doxycycline-patient-drug-information\" class=\"drug drug_patient\">Doxycycline: Patient drug information</a></li></ul></div></div>","javascript":null}